What records are connected here?
- Evidence lanes
- 3
- Source years
- 16
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved2Evidence: Large human trialsInfections
Enfuvirtide is a synthetic peptide that blocks HIV-1 from fusing with human cells. It is the active ingredient in Fuzeon, which FDA approved in 2003.1,2,3 In the randomized TORO 2 trial of 512 people with drug-resistant HIV-1, adding enfuvirtide to an optimized drug combination lowered the amount of virus in the blood more than the combination alone over 24 weeks.3 Drugs@FDA now lists Fuzeon as discontinued.2
| What it is | A synthetic peptide HIV-1 fusion inhibitor, also recorded as DP-178 and T-20 in FDA’s substance registry.1,3 |
|---|---|
| FDA status | FDA-approved, but discontinued. Drugs@FDA lists Fuzeon, NDA 021481, with an original approval date of March 13, 2003, and lists the product as discontinued.2 |
| Human evidence | Large randomized Phase 3 trials, including TORO 2 in 512 people with drug-resistant HIV-1, published in 2003.3 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Enfuvirtide is a synthetic peptide that FDA’s substance registry also records as DP-178 and T-20, and under the brand name Fuzeon.1
In the United States it is the active ingredient of Fuzeon, approved under NDA 021481, according to Drugs@FDA.2
The TORO 2 investigators describe enfuvirtide as a fusion inhibitor: it acts against HIV-1 at the step where the virus fuses with a cell, a different target from the other classes of HIV drugs their patients had already received.3
TORO 2 randomized 512 people who had taken all three earlier classes of HIV drugs, had resistance to them, or both, to an optimized combination with or without enfuvirtide.3
After 24 weeks, the amount of virus in the blood fell more with enfuvirtide added, and CD4 immune cell counts rose more (by about 66 versus 38 cells per cubic millimetre), according to the trial report.3
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes, but the product is no longer sold. Drugs@FDA lists Fuzeon, application NDA 021481, with an original approval date of March 13, 2003, and lists Fuzeon as discontinued.2
The sources reviewed here do not report that FDA has withdrawn the approval.2
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list enfuvirtide.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Enfuvirtide is not among them.5,6
Its longer-term effect: TORO 2 compared the treatments over 24 weeks.3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Enfuvirtide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Enfuvirtide are a bounded selection, not every registration or paper about Enfuvirtide. For the years before Enfuvirtide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Enfuvirtide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Enfuvirtide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Fuzeon for HIV-1; discontinued. In a randomized trial of 512 people with drug-resistant HIV-1, adding enfuvirtide lowered virus levels more than an optimized combination alone. Enfuvirtide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Fuzeon for HIV-1; discontinued. In a randomized trial of 512 people with drug-resistant HIV-1, adding enfuvirtide lowered virus levels more than an optimized combination alone. Enfuvirtide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 11, 2026
Enfuvirtide.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
Enfuvirtide.↗Source date October 11, 2026Literature metadata · added November 16, 2026
Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.↗Source date May 18, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT00302822↗Source date April 7, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
22 of 22 selected trial records include at least one phase value; 22 of 22 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00002228 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00002239 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-11-15, and PeptideScanner's reviewed identity mapping was enfuvirtide.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span March 13, 2003 to October 11, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 14664654 in Drugs as Journal Article, Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗
Literature metadata
PubMed lists PMID 17288910 in Enfermedades infecciosas y microbiologia clinica as Consensus Statement, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20001856 in The Journal of infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2010-01-15 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35646620 in Biotechnology reports (Amsterdam, Netherlands) as Journal Article, with publication-date metadata of 2022-05-14 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 17389560 in Journal of clinical pharmacology as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
The New England Journal of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026